SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John J H Kim who wrote (5146)1/30/1998 3:34:00 PM
From: Tunica Albuginea  Read Replies (1) of 23519
 
John, <<is there something better than "painfull intraurethral MUSE"
on the market? >>is what you are asking.The answer is no. In medicine you don't always have an easy solution to a difficult problem. We are
looking for one.Until then people will use MUSE. Vivus is working on other local intraurethral products.Hopefully less painful.Local therapy though is the key in medicine less exposure to systemic side effects. This is why MUSE now at 600,000 patients per year equals in only 1 year in the market the equivalent of all the patients taking the needle. Pain from MUSE is not that bad. Furhtermore, once into sexual activity, the plaesure sensation overrides in the brain the painfull sensation.A well known fact where men will continue intercourse even if they have painfull abrasions in the galns penis from too much friction. The plewsure / pain equqtion is resolved in the brain.

TA ( who thinks he is a doctor, gg ).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News